Share on

Global Breast Biopsy Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Type, Product, Guidance & Region - Industry Forecast (2022 to 2027)

Published: January, 2022
ID: 4101
Pages: 175
Formats: report pdf report excel report power bi report ppt

Global Breast Biopsy Market Size (2022 to 2027)

The global breast biopsy market is predicted to grow to USD 1104.89 Million by 2027 from USD 658.36 million in 2022, growing at a CAGR of 10.91% during the forecast period.

A breast biopsy is a test performed to remove tissue or fluid from a diseased area of the patient’s body, while the extracted sample is further examined to check the presence of breast cancer. There are different types of biopsy procedures depending on the product, such as vacuum-assisted biopsy (VAB), core needle biopsy (CNB), and fine-needle aspiration biopsy (FNAB), recommended by the doctor based on the location, size, and other characteristics of the breast abnormality. The various techniques of the biopsy market work quickly and are simple. As a result, the results are fast and accurate.


Y-O-Y growth in the incidence of breast cancer is primarily driving the global breast biopsy market growth.

An increase in breast cancer incidence in women, especially around the age of 40, and growth in awareness regarding breast cancer screening programs drive the market growth. According to the statistics of, the United States had an estimated new 276,480 invasive and 48,530 non-invasive breast cancer cases in 2020. They further stated that 1 in every 8 women are likely to develop breast cancer in their lifetime in the United States.

The emergence of technologically advanced and minimally invasive breast biopsy devices is expected to provide these untapped market opportunities. In addition, growing awareness regarding breast biopsy across the world and the increasing geriatric ladies' populace is further expected to add a boost to the growth rate of the breast biopsy market.


The restraints in this market include the high cost of procedure and demand skewed towards a specific gender and middle age to the elderly age group, eliminating a significant chunk of the population segment. In addition, the risk of infection due to improper care of breast biopsy cuts and wounds and uncertain regulatory guidelines for medical devices are likely to limit the growth of the global breast biopsy market.

Impact of COVID-19 on the global breast biopsy market:

COVID-19 has affected many sectors differently and has been declared a pandemic by World Health Organisation (WHO). The global economy was drastically decreased due to the coronavirus. Lockdown has influenced so many industries in several ways, where some industries were impacted badly, and some gained profits. The Breast Biopsy Market is not an exception. The Global Breast Biopsy Market has gone through some rough times during the pandemic. Due to the lockdown, the patient flow has slowed since the restricted access to clinics and hospitals, which affected the Breast Biopsy Market. The fear in people about COVID 19 dragged people from getting diagnosed during the pandemic. Moreover, the breast biopsy devices required for breast biopsy treatment had not been delivered to the hospitals due to the pandemic, which hammered the market. But, after the pandemic, the market is getting profits. The key players in the market are introducing new devices like Ultrasound Guided Breast Biopsy Devices to sustain the market competition.




Market Size Available

2021 to 2027

Base Year


Forecast Period

2022 to 2027

Segments Covered

By Product, Type, Guidance, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa


This market research report on the global breast biopsy market has been segmented and sub-segmented based on the product, type, guidance, and region.

Breast Biopsy Market – By Product:

  • Biopsy needles      
  • Guidance systems               
  • Biopsy tables          
  • Localization wires 
  • Others      

The biopsy needles held a significant market share based on the product and are estimated to grow at a CAGR of 12.1% during the forecast period. The rapid rise in the adoption of Biopsy needles in hospitals and clinics due to its advantages, like high sensitivity and specificity, drives the Biopsy needle segment. In addition, the advancements in technological devices are boosting the market. For example, Stryker PreciseCore needles allow sample acquisition with higher precision and considerably more negligible tissue damage risks. Moreover, the Biopsy Needles provide a more accurate assessment of breast mass than fine-needle aspiration. Therefore, the Guidance Systems segment is predominantly rising during the forecast period.

Breast Biopsy Market – By Type:

  • Needle Breast Biopsy         
    • Core Needle Biopsy
    • Fine Needle Aspiration Biopsy
    • Vacuum-Assisted Biopsy
  • Open Surgical Breast Biopsy             
    • Excisional Breast Biopsy
    • Incisional Breast Biopsy

Based on type, Vacuum-assisted biopsy accounts for a significant portion of the revenue. These devices can accurately locate the abnormality area without any difficulties, and the less-invasive nature of this technique is driving the vacuum-assisted biopsy segment. The increase in usage of vacuum-assisted biopsy is boosting the segment. The Fine Needle Aspiration Biopsy is significantly growing during the forecast period. The demand for minimally invasive procedures and technological devices drives the Needle Aspiration Biopsy segment.

Breast Biopsy Market – By Guidance:

  • Mammography-Guided Stereotactic Breast Biopsy
  • Ultrasound-Guided Breast Biopsy
  • MRI-Guided Breast Biopsy
  • Other Guidance Techniques

The ultrasound segment is expected to be the fastest-growing based on guidance. It is the quickest technique among all, which is driving the Ultrasound-Guided Breast Biopsy segment. It also decreases the need for ionizing radiation exposure and is opposite to the conventional mammography-guided stereotactic biopsy procedure. These are the factors boosting the Ultrasound-Guided Breast Biopsy segment growth. As a result, the mammography-guided segment is estimated to grow at the highest CAGR during the forecast period. 

Breast Biopsy Market – By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

The global breast biopsy market was dominated by North America, followed by Europe in 2020. Asia Pacific is expected to grow at the highest CAGR. During the forecast period, the North American Breast Biopsy Market size is forecasted to grow at a CAGR of 10.5% due to the growing incidence of breast cancer in this region and the quick adoption of technological advancements. In this region, the United States market is predicted to account majority share during the forecast period. Breast cancer awareness is significantly growing in the U.S., and the ongoing technological advancements in the treatment options are expected to fuel the U.S. breast biopsy market during the forecast period. Conversely, the Canadian market is projected to rise at a lucrative growth rate during the forecast period.

Europe was the second-largest regional market globally in 2020 and was worth USD 126.55 million in 2021. Therefore, countries like the U.K. and Germany are expected to have lucrative growth opportunities during the forecast period in this regional market.

The Asia-Pacific market is forecasted to be the fastest-growing region in the global market during the forecast period. Across the globe, Asia has the highest percentage of an aging population. In addition, in the recent past, a significant spike in breast cancer incidence in this region is expected to drive this regional market during the forecast period.

The Latin American Breast Biopsy market is predicted to be worth USD 89.87 million by 2026. Countries like Brazil and Mexico are projected to grow significantly during the forecast period in this region.


The list of key players included in the report consists of Hologic Inc., Leica Biosystems Nussloch GmbH (Devicor Medical Products, Inc.), C. R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule medical Devices LLC., Ethicon Endo-Surgery (Johnson & Johnson), Intact Medical Corporation, and Galini SRL.


  • Hologic's Brevera Breast Biopsy System with CorLumina Imaging Technology gained European CE mark clearance in 2018. This technology enhances biopsy accuracy, patient satisfaction, and workflow in the biopsy suite with real-time imaging.
  • Hologic announced introducing their CorLumina Imaging Technology Brevera breast biopsy system for commercial access in the United States in 2017. It is developed with real-time imaging to boost the accuracy of the biopsy, improve patient experience and simplify the biopsy from start to end.
  • Mayo Clinic and Imago Systems Image Visualization Company cooperated on Breast Imaging in August 2019.
  • Dune Medical Devices announced the first-in-man test of their smart biopsy instrument in March 2019. Dune Medical's Smart Biopsy is a percutaneous soft tissue biopsy tool that uses tiny key needle detectors to provide real-time electrical samples. These electrical pulses are compared to histological data to improve diagnosis and readout. The in-man stage marks the commencement of a more extensive, more thorough clinical study aimed at determining the specific tissue composition of the breast.
  • C. R. Bard Inc. was purchased by Becton, Dickinson, and Company (BD) for $16.0 billion. The merged firm is anticipated to enhance illness treatment and provide more convenience to healthcare professionals. Furthermore, C.R. Bard's robust product portfolio and innovation pipeline will expand BD's potential in fast-growing clinical areas and the combined company's growth opportunities outside of the United States.

Please wait. . . . Your request is being processed


How much was the global breast biopsy market worth in 2021?

The global breast biopsy market was valued at USD 593.5 million in 2021.

Does this report include the impact of COVID-19 on the breast biopsy market?

COVID-19 has shown a significant negative impact on the breast biopsy market in the initial days and a detailed analysis of how has COVID-19 impacted the breast biopsy market is included in this report.

Which region had the largest share of the global breast biopsy market?

In 2021, the North American region accounted for the leading share of the breast biopsy market.

Who are the major players in the breast biopsy market?

Hologic Inc., Leica Biosystems Nussloch GmbH (Devicor Medical Products, Inc.), C. R. Bard, Inc., Becton and Dickinson Company, Argon Medical Devices, Cook Medical Incorporated, Encapsule medical Devices LLC., Ethicon Endo-Surgery (Johnson & Johnson), Intact Medical Corporation, and Galini SRL. are some of the notable players in the breast biopsy market.

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample